FDA panel rejects MDMA therapy for PTSD

FDA panel rejects MDMA therapy for PTSD

On June 4, a panel of U.S. Food and Drug Administration (FDA) advisors voted against recommending MDMA-assisted therapy as a treatment for post-traumatic stress disorder (PTSD).  The panel examined the results from two clinical trials carried out by Lykos Therapeutics...